Physician profile
Jack David Schim
NPI 1346276375
$1,703,869.43
in general payments reported to CMS, 2019-2025
52 companies · $126K in 2025
The $126K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443K · 2020: $288K · 2021: $371K · 2022: $290K · 2023: $125K · 2024: $60K · 2025: $126K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $138K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Honoraria: $61K · Travel and Lodging: $34K · Food and Beverage: $9,873 · Education: $85.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $138,115.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $68,325.00 |
| Honoraria | $60,526.00 |
| Travel and Lodging | $34,064.23 |
| Food and Beverage | $9,872.90 |
| Education | $85.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $309,286.83 | 2019-2022 | |
| Abbvie INC. | $271,626.66 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Lilly USA, LLC | $252,749.34 | 2019-2024 | Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $214,056.36 | 2019-2025 | Ajovy, Austedo, Austedo Xr |
| Amgen INC. | $177,521.61 | 2019-2025 | Aimovig, Uplizna |
| Ipsen Innovation | $104,547.39 | 2023-2025 | Dysport |
| Biohaven Pharmaceuticals, INC. | $77,600.22 | 2020-2021 | |
| Lundbeck LLC | $66,616.61 | 2019-2025 | Vyepti |
| Impel Pharmaceuticals INC. | $50,671.37 | 2022-2023 | Trudhesa |
| Axsome Therapeutics, INC. | $47,925.51 | 2024-2025 | Symbravo |
| Novartis Pharma Ag | $29,470.07 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $26,397.73 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25,898.13 | 2022 | |
| Pfizer INC. | $14,635.90 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $6,455.98 | 2019-2020 |
Show all 51 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Schim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.